TAIPEI, March 17, 2025 /PRNewswire/ -- Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in combination with current medications for ...
Microbio (4128) has delivered a -38.41% change over the past year, with a 52-week range between 17.90 and 35.65. What Is the Average Daily Trading Volume of Microbio (4128)? The average daily trading ...
BRISBANE, Australia, Nov. 29, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has appointed Paul Brennan as ...
Leo Pharma is paying $40 million upfront and $530 million in biobucks to license a midstage experimental eczema and asthma drug. The therapy, FB825, has been developed by Oneness Biotech and Microbio ...
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, ...
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer ...
Brisbane medtech scale-up Microbio has developed a game-changing pathogen test to help identify “a silent killer” that is notoriously difficult to predict, diagnose and treat, as the signs and ...
Microbio (Shanghai) Co. Ltd. has synthesized glucagon-like peptide 1 receptor (GLP1R) agonists reported to be useful for the treatment of obesity, type 2 diabetes and nonalcoholic fatty liver disease.
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer ...
Visit a quote page and your recently viewed tickers will be displayed here.
4147.TWO TaiMed Biologics Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results